Format

Send to

Choose Destination
J Infect. 2016 Jun;72(6):713-722. doi: 10.1016/j.jinf.2016.02.017. Epub 2016 Mar 24.

17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.

Author information

1
Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: rosannewieten@icloud.com.
2
Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
3
Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
4
Institute for Tropical Diseases, Harbour Hospital, Rotterdam, the Netherlands.
5
Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
6
Renal Transplant Unit, Division of Internal Medicine, Academic Medical Center, the Netherlands.

Abstract

BACKGROUND:

The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients.

MATERIALS AND METHODS:

Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers.

RESULTS:

The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time.

CONCLUSION:

These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains.

KEYWORDS:

17D yellow fever; Immune-compromised; Vaccination

PMID:
27017899
DOI:
10.1016/j.jinf.2016.02.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center